Nanoparticles; Data on Nanoparticles Discussed by Researchers at Faculty of Pharmacy

Press/Media: Article/Feature

Description

2014 JAN 20 (VerticalNews) -- By a News Reporter-Staff News Editor at Nanotechnology Weekly -- Researchers detail new data in Nanoparticles. According to news originating from New Delhi, India, by VerticalNews correspondents, research stated, "The purpose of the present study was to investigate the potential of Venlafaxine loaded alginate nanoparticles (VLF AG-NPs) for treatment of depression via intranasal (i.n.) nose to brain delivery route. The VLF AG-NPs were prepared and optimized on the basis of various physio-chemical characteristics."

Our news journalists obtained a quote from the research from the Faculty of Pharmacy, "Pharmacodynamic studies of the VLF AG-NPs for antidepressant activity were carried in-vivo by forced swimming test and locomotor activity test on albino Wistar rats. VLF AG-NPs(i.n.) treatment significantly improved the behavioural analysis parameters i.e. swimming, climbing, and immobility in comparison to the VLF solution(i.n.) and VLF tablet(oral). The intranasal VLF AG-NPs also improved locomotor activity when compared with VLF solution(i.n.) and VLF tablet(oral). Confocal laser scanning fluorescence microscopy studies were performed on isolated organs of rats after intravenous and intranasal administrations of Rodamine-123 loaded alginate nanoparticles to determine its efficacy for nose to brain delivery and also for its qualitative distribution to other organs. Brain uptake and pharmacokinetic studies were performed by determination of VLF concentration in blood and brain respectively for VLF AG-NPs(i.n.), VLF solution(i.n.) and VLF solution(i.v.). The greater brain/blood ratios for VLF AG-NPs(i.n.) in comparison to VLF solution(i.n.) and VLF solution(i.n.) respectively at 30 min are indicative of superiority of alginate nanoparticles for direct nose to brain transport of VLF."

According to the news editors, the research concluded: "Thus, VLF AG-NPs(i.n.) delivered greater VLF to the brain in comparison to VLF solution which indicates that VLF AG-NPs could be a promising approach for the treatment of depression."

For more information on this research see: Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. Journal of Psychiatric Research, 2014;48(1):1-12. Journal of Psychiatric Research can be contacted at: Pergamon-Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England. (Elsevier - www.elsevier.com; Journal of Psychiatric Research - www.elsevier.com/wps/product/cws_home/241)

The news correspondents report that additional information may be obtained from S. Haque, Jamia Hamdard, Fac Pharm, Dept. of Pharmaceut, New Delhi 110062, India. Additional authors for this research include S. Md, J.K. Sahni, J. Ali and S. Baboota.

Keywords for this news article include: Asia, India, New Delhi, Treatment, Nanotechnology, Emerging Technologies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

Period20 Jan 2014

Media coverage

1

Media coverage

  • TitleNanoparticles; Data on Nanoparticles Discussed by Researchers at Faculty of Pharmacy
    Degree of recognitionInternational
    Media name/outletNanotechnology Weekly/NewsRx
    Media typePrint
    CountryUnited States of America
    Date20/01/14
    Description 2014 JAN 20 (VerticalNews) -- By a News Reporter-Staff News Editor at Nanotechnology Weekly -- Researchers detail new data in Nanoparticles. According to news originating from New Delhi, India, by VerticalNews correspondents, research stated, "The purpose of the present study was to investigate the potential of Venlafaxine loaded alginate nanoparticles (VLF AG-NPs) for treatment of depression via intranasal (i.n.) nose to brain delivery route. The VLF AG-NPs were prepared and optimized on the basis of various physio-chemical characteristics."

    Our news journalists obtained a quote from the research from the Faculty of Pharmacy, "Pharmacodynamic studies of the VLF AG-NPs for antidepressant activity were carried in-vivo by forced swimming test and locomotor activity test on albino Wistar rats. VLF AG-NPs(i.n.) treatment significantly improved the behavioural analysis parameters i.e. swimming, climbing, and immobility in comparison to the VLF solution(i.n.) and VLF tablet(oral). The intranasal VLF AG-NPs also improved locomotor activity when compared with VLF solution(i.n.) and VLF tablet(oral). Confocal laser scanning fluorescence microscopy studies were performed on isolated organs of rats after intravenous and intranasal administrations of Rodamine-123 loaded alginate nanoparticles to determine its efficacy for nose to brain delivery and also for its qualitative distribution to other organs. Brain uptake and pharmacokinetic studies were performed by determination of VLF concentration in blood and brain respectively for VLF AG-NPs(i.n.), VLF solution(i.n.) and VLF solution(i.v.). The greater brain/blood ratios for VLF AG-NPs(i.n.) in comparison to VLF solution(i.n.) and VLF solution(i.n.) respectively at 30 min are indicative of superiority of alginate nanoparticles for direct nose to brain transport of VLF."

    According to the news editors, the research concluded: "Thus, VLF AG-NPs(i.n.) delivered greater VLF to the brain in comparison to VLF solution which indicates that VLF AG-NPs could be a promising approach for the treatment of depression."

    For more information on this research see: Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. Journal of Psychiatric Research, 2014;48(1):1-12. Journal of Psychiatric Research can be contacted at: Pergamon-Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England. (Elsevier - www.elsevier.com; Journal of Psychiatric Research - www.elsevier.com/wps/product/cws_home/241)

    The news correspondents report that additional information may be obtained from S. Haque, Jamia Hamdard, Fac Pharm, Dept. of Pharmaceut, New Delhi 110062, India. Additional authors for this research include S. Md, J.K. Sahni, J. Ali and S. Baboota.

    Keywords for this news article include: Asia, India, New Delhi, Treatment, Nanotechnology, Emerging Technologies

    Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
    URLhttps://search.proquest.com/docview/1477837818?accountid=12528&rfr_id=info%3Axri%2Fsid%3Aprimo
    PersonsShadab Haque